Lippincott ® NursingCenter ® Wolters Kluwer Logo

Web-Banner-for-LNC.jpg

New Drug Indications - July 2025

ipilimumab

Yervoy
Pharmaceutical company: Bristol-Myers Squibb


NEW INDICATION & DOSAGE
Unresectable or microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in combination with nivolumab
Adults and children ages 12 and older weighing 40 kg or more: 1-mg/kg IV infusion immediately following nivolumab 240-mg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.
Children ages 12 and older weighing less than 40 kg: 1-mg/kg IV infusion immediately following nivolumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.

Unresectable or metastatic hepatocellular cancer in combination with nivolumab
Adults: 3-mg/kg IV infusion immediately following nivolumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.

Released: July 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

nivolumab

Opdivo
Pharmaceutical company: Bristol-Myers Squibb


NEW INDICATION & DOSAGE
Unresectable or microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer in combination with ipilimumab
Adults and children ages 12 and older weighing 40 kg or more: 240-mg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.
Children ages 12 and older weighing less than 40 kg: 3-mg/kg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.

Unresectable or metastatic hepatocellular cancer in combination with ipilimumab
Adults: 1-mg/kg IV infusion followed by ipilimumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.

Released: July 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

upadacitinib

Rinvoq
Pharmaceutical company: AbbVie


NEW INDICATION & DOSAGE
Giant cell arteritis
Adults: 15 mg PO daily in combination with a tapering course of corticosteroids. May continue as monotherapy after corticosteroids are stopped.

Released: July 2025

Nursing Drug Handbook

© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.

New Drug Indications Archive

New Drug Indications - July 2025
ipilimumabYervoyPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGEUnresectable or microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in combination with nivolumabAdults and children ages 12 and older weighing 40 kg or more: 1-mg/kg IV infusion immediately following nivolumab 240-mg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.Children ages 12 and older weighing less than 40 kg: 1-mg/kg IV infusion immediately following nivolumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.Unresectable or metastatic hepatocellular cancer in combination with nivolumabAdults: 3-mg/kg IV infusion immediately following nivolumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses. After completion of combination therapy, continue nivolumab as a single agent per nivolumab manufacturer's instructions.Released: July 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.nivolumabOpdivoPharmaceutical company: Bristol-Myers SquibbNEW INDICATION & DOSAGEUnresectable or microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer in combination with ipilimumabAdults and children ages 12 and older weighing 40 kg or more: 240-mg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.Children ages 12 and older weighing less than 40 kg: 3-mg/kg IV infusion followed by ipilimumab 1-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.Unresectable or metastatic hepatocellular cancer in combination with ipilimumabAdults: 1-mg/kg IV infusion followed by ipilimumab 3-mg/kg IV infusion on the same day every 3 weeks for a maximum of 4 doses; then 240 mg every 2 weeks or 480 mg every 4 weeks as a single agent until disease progression, unacceptable toxicity occurs, or for up to 2 years.Released: July 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.upadacitinibRinvoqPharmaceutical company: AbbVieNEW INDICATION & DOSAGEGiant cell arteritisAdults: 15 mg PO daily in combination with a tapering course of corticosteroids. May continue as monotherapy after corticosteroids are stopped.Released: July 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
New Drug Indications - June 2025
apixabanEliquisPharmaceutical company: Bristol-Myers Squibb Company and Pfizer Inc.NEW FORM:Capsule for oral suspension: 0.15 mgTablet for oral suspension: 0.5 mgNEW INDICATION & DOSAGETreatment of VTE and reduction in risk of recurrent VTE after at least 5 days of initial anticoagulant treatmentChildren weighing 35 kg or more: 10 mg PO b.i.d. days 1 to 7, then 5 mg b.i.d.Children weighing 25 to less than 35 kg: 8 mg PO b.i.d. days 1 to 7, then 4 mg b.i.d.Children weighing 18 to less than 25 kg: 6 mg PO b.i.d. days 1 to 7, then 3 mg b.i.d.Children weighing 12 to less than 18 kg: 4 mg PO b.i.d. days 1 to 7, then 2 mg b.i.d.Children weighing 9 to less than 12 kg: 3 mg PO b.i.d. days 1 to 7, then 1.5 mg b.i.d.Children weighing 6 to less than 9 kg: 2 mg PO b.i.d. days 1 to 7, then 1 mg b.i.d.Children weighing 4 to less than 6 kg: 1 mg PO b.i.d. days 1 to 7, then 0.5 mg b.i.d.Children weighing 2.6 to less than 4 kg: 0.3 mg PO b.i.d. days 1 to 7, then 0.15 mg b.i.d.Adjust-a-dose: Individualize therapy duration based on bleeding risk assessment.Released: June 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.diazepamValtocoPharmaceutical company: Neurelis, Inc.NEW INDICATION & DOSAGEAcute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from usual seizure pattern in patients with epilepsy (intranasal)Children ages 2 to 5 weighing 23 to 33 kg: 7.5 mg intranasally in both nostrils (15 mg total).Children ages 2 to 5 weighing 12 to 22 kg: 10mg intranasally in one nostril (10 mg total).Children ages 2 to 5 weighing 6 to 11 kg: 5 mg intranasally in one nostril (5 mg total).Adjust-a-dose: If a second dose is needed, give at least 4 hours after initial dose. Don't use more than two doses to treat a single episode.Released: June 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.palbociclibIbrancePharmaceutical company: Pfizer, Inc.NEW INDICATION & DOSAGEEndocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with inavolisib and fulvestrant following recurrence on or after completing adjuvant endocrine therapyAdult males or adult females who are postmenopausal: 125 mg PO daily for 21 consecutive days followed by 7 days off to complete a cycle of 28 days. Treat patients who are premenopausal and perimenopausal with a luteinizing hormone-releasing hormone (LHRH) agonist according to current standards. Male patients should be considered for treatment with an LHRH agonist according to current standards. See manufacturer's instructions for inavolisib and fulvestrant dosing information.Adjust-a-dose: For patients with Child-Pugh class C liver impairment, decrease dosage to 75 mg PO daily. If concomitant use of strong CYP3A inhibitors is unavoidable, decrease palbociclib dosage to 75 mg daily. If strong inhibitor is discontinued, increase palbociclib dosage after three to five half-lives have passed from CYP3A inhibitor dose. See manufacturer's instructions.Released: June 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.tedizolidSivextroPharmaceutical company: Merck & Co., Inc.NEW INDICATION & DOSAGEAcute bacterial skin and skin-structure infections caused by susceptible gram-positive isolates (Staphylococcus aureus [including MRSA and methicillin-susceptible strains], Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group [including S. anginosus, S. intermedius, and S. constellatus], and Enterococcus faecalis)Children weighing 35 kg or more: 200 mg PO or IV daily for 6 days.Children at least 26 weeks gestation weighing 20 to less than 35 kg: 60-mg IV infusion b.i.d. for 6 days.Children at least 26 weeks gestation weighing 14 to less than 20 kg 40-mg IV infusion b.i.d. for 6 days.Children at least 26 weeks gestation weighing 10 to less than 14 kg: 30-mg IV infusion b.i.d. for 6 days.Children at least 26 weeks gestation weighing 6 to less than 10 kg: 20-mg IV infusions b.i.d. for 6 days.Children at least 26 weeks gestation weighing 3 to less than 6 kg: 12-mg IV infusion b.i.d. for 6 days.Children at least 26 weeks gestation weighing 2 to less than 3 kg: 6-mg IV infusion b.i.d. for 6 days.Children at least 26 weeks gestation weighing 1 to less than 2 kg: 3-mg/kg IV infusion b.i.d. for 6 days.Released: June 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
New Drug Indications - May 2025
cabozantinibCabometyxPharmaceutical company: Exelixis, Inc.NEW INDICATION & DOSAGEPreviously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors (Cabometyx only)Adults and children ages 12 and older weighing 40 kg or more: 60 mg PO daily until disease progression or unacceptable toxicity.Children ages 12 and older weighing less than 40 kg: 40 mg PO daily until disease progression or unacceptable toxicity.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.durvalumabImfinziPharmaceutical company: AstraZenecaNEW INDICATION & DOSAGEMuscle-invasive bladder cancerAdults weighing 30 kg or more: 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery.Adults weighing less than 30 kg: 20 mg/kg IV every 3 weeks in combination with gemcitabine and cisplatin for 4 cycles prior to surgery, followed by 20 mg/kg IV every 4 weeks as a single agent for up to 8 cycles after surgery.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.eculizumabSolirisPharmaceutical company: Alexion PharmaceuticalsNEW INDICATION & DOSAGEGeneralized myasthenia gravis in patients who are anti-acetylcholine receptor antibody positiveChildren ages 6 and older weighing 40 kg or more: 900 mg IV once every 7 days for 4 weeks, then 1,200 mg IV 7 days later (week 5), followed by 1,200 mg IV every 2 weeks thereafter.Children ages 6 and older weighing 30 to less than 40 kg: 600 mg IV once every 7 days for 2 weeks, then 900 mg IV 7 days later (week 3), followed by 900 mg IV every 2 weeks thereafter.Children ages 6 and older weighing 20 to less than 30 kg: 600 mg IV once every 7 days for 2 weeks, then 600 mg IV 7 days later (week 3), followed by 600 mg IV every 2 weeks thereafter.Children ages 6 and older weighing 10 to less than 20 kg: 600 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 2 weeks thereafter.Children ages 6 and older weighing 5 to less than 10 kg: 300 mg IV once every 7 days on week 1, then 300 mg IV 7 days later (week 2), followed by 300 mg IV every 3 weeks thereafter.Adjust-a-dose: Give a supplemental dose within 60 minutes after each plasmapheresis or plasma exchange session. If the most recent dose was 300 mg, give 300-mg supplemental dose. If the most recent dose was 600 mg or more, give 600-mg supplemental dose. For patients receiving fresh frozen plasma, if the most recent dose was 300 mg or more, give 300-mg supplemental dose 1 hour before each unit of fresh frozen plasma. In a patient receiving concomitant IV immunoglobulin treatment, refer to the manufacturer's instructions for supplemental eculizumab dose requirements and timing.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.emtricitabine-rilpivirine-tenofovir alafenamideOdefseyPharmaceutical company: Gilead SciencesNEW INDICATION & DOSAGEHIV-1 infection as initial therapy in patients with no antiretroviral treatment history and HIV-1 RNA of 100,000 copies/mL or less; or to replace a stable antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual componentsChildren ages 6 and older weighing at least 25 kg: 1 tablet PO daily with a meal.Adjust-a-dose: For patients on hemodialysis, give 1 tablet daily; give after hemodialysis on dialysis days. This drug isn't recommended for patients with creatinine clearance of less than 30 mL/minute or in patients with chronic kidney disease who aren't receiving long-term dialysis.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.epinephrineNeffyPharmaceutical company: ARS PharmaNEW AVAILABLE FORMNasal spray: 1 mg/0.1 mL per single-dose sprayNEW INDICATION & DOSAGEType I allergic reactions, including anaphylaxisAdults and children ages 4 and older weighing 15 to less than 30 kg: One spray (1 mg) into one nostril. If there is no clinical response or worsening symptoms, repeat the dose after 5 minutes in the same nostril.  Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.furosemideFuroscixPharmaceutical company: scPharmaceuticalsNEW INDICATION & DOSAGEEdema in patients with chronic kidney disease, including the nephrotic syndromeAdults: Subcutaneous on-body infusor with prefilled cartridge preprogrammed to deliver 30 mg over first hour, followed by 12.5 mg per hour for subsequent 4 hours. Total dose, 80 mg over 5 hours.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.glucagonBaqsimiPharmaceutical company: Amphastar PharmaceuticalsNEW INDICATION & DOSAGESevere hypoglycemia in patients with diabetesChildren ages 1 and older: 3 mg (one actuation of intranasal device) into one nostril. If there is no response after 15 minutes, the dose may be repeated.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.pembrolizumabKeytrudaPharmaceutical company: MerckNEW INDICATION & DOSAGEFirst-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapyAdults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease recurrence. Give before trastuzumab and chemotherapy, when given the same day.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.tenecteplaseTNKasePharmaceutical company: GenentechNEW INDICATION & DOSAGEAcute ischemic strokeAdults weighing 90 kg or more: 25 mg (5 mL) by IV bolus over 5 seconds.Adults weighing 80 to less than 90 kg: 22.5 mg (4.5 mL) by IV bolus over 5 seconds.Adults weighing 70 to less than 80 kg: 20 mg (4 mL) by IV bolus over 5 seconds.Adults weighing 60 to less than 70 kg: 17.5 mg (3.5 mL) by IV bolus over 5 seconds.Adults weighing less than 60 kg: 15 mg (3 mL) by IV bolus over 5 seconds.Adjust-a-dose: Begin treatment as soon as possible and within 3 hours of the onset of stroke symptoms.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.tesamorelin acetateEgrifta WRPharmaceutical company: TheratechnologiesNEW AVAILABLE FORMInjection (Egrifta WR):11.6-mg vialsNEW INDICATION & DOSAGEReduction of excess abdominal fat in patients infected with HIV-1 with lipodystrophyAdults: Inject 1.28 mg (0.16 mL) subcut once daily in abdomen.Released: May 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
New Drug Indications - April 2025
apomorphine hydrochlorideOnapgoPharmaceutical company: Supernus PharmaceuticalsNEW AVAILABLE FORMSolution for infusion: 98 mg/20 mL (4.9 mg/mL) in single-dose cartridgesNEW INDICATION & DOSAGEMotor fluctuations in patients with advanced Parkinson diseaseAdults: Initially, 1 mg/hr subcut infusion for up to 16 hours per day. Titrate, as needed, no more than once per day in 0.5 mg/hr to 1 mg/hr increments. Maximum, 6 mg/hr while awake during the day, up to 16 hours. May give bolus dose when starting the infusion in the morning, when restarting the infusion after a 1-hour or longer break, or to supplement continuous infusion to manage acute, uncontrolled "off" symptoms. Titrate bolus dose to clinical response and tolerance in increments of 0.5 mg or 1 mg. Maximum bolus, 2 mg. Give no more than 3 bolus doses per day with at least 3 hours between doses. Consider increasing the continuous infusion rate if 3 bolus doses/day are routinely required. Total maximum daily dosage, including bolus doses, is 98 mg.Adjust-a-dose: In patients with mild to moderate kidney impairment, don't exceed 1 mg for initial bolus dose.Released: April 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.brentuximab vedotinAdcetrisPharmaceutical company: Pfizer, Inc.NEW INDICATION & DOSAGERelapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in patients who are not eligible for autologous hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapy, in combination with lenalidomide and rituximabAdults: 1.2-mg/kg IV infusion every 3 weeks or until disease progression or unacceptable toxicity occurs. Maximum dose, 120 mg. Give with granulocyte colony-stimulating factor beginning cycle 1.Adjust-a-dose: In patients with normal total bilirubin and AST greater than the upper limit of normal (ULN), or total bilirubin more than 1 to 1.5 x ULN and any AST, reduce dosage to 0.9 mg/kg every 3 weeks. Maximum dose, 90 mg. Avoid use in patients with total bilirubin more than 1.5 x ULN.Released: April 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.ranibizumabSusvimoPharmaceutical company: GenentechNEW INDICATION & DOSAGEDiabetic macular edema in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor (Susvimo)Adults: 2 mg (0.02 mL of 100 mg/mL solution) continuous delivery by ocular implant with refills every 24 weeks.Adjust-a-dose: May give a supplemental intravitreal injection to affected eye, with ocular implant in place, if needed.Released: April 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.semaglutideOzempicPharmaceutical company: Novo NordiskNEW INDICATION & DOSAGEReduce risk of sustained estimated GFR decline, kidney failure, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (Ozempic only)Adults: Initially, 0.25 mg subcut once weekly for 4 weeks; then increase to 0.5 mg once weekly. After 4 weeks, increase to maintenance dose of 1 mg once weekly.Released: April 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
New Drug Indications - March 2025
acalabrutinibCalquencePharmaceutical company: AstraZenecaNEW INDICATION & DOSAGETreatment of previously untreated mantle cell lymphoma in combination with bendamustine and rituximab in patients who are ineligible for autologous hematopoietic stem cell transplantationAdults: 100 mg PO every 12 hours until disease progression or unacceptable toxicity occurs. Give bendamustine 90 mg/m2 IV on days 1 and 2, and rituximab 375 mg/m2 IV on day 1 of cycle 1 and continue for a total of six 28-day cycles. Patients achieving a partial or complete response after the first six cycles may continue maintenance rituximab on day 1 of every other cycle for a maximum of 12 additional doses, starting on cycle 8 up to cycle 30. Refer to bendamustine and rituximab prescribing information for additional information.Treatment of previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma in combination with obinutuzumabAdults: 100 mg PO every 12 hours until disease progression or unacceptable toxicity occurs. Start obinutuzumab on day 1 of cycle 2 for a total of six 28-day cycles. Refer to the obinutuzumab prescribing information for dosing and additional information.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.canagliflozinInvokanaPharmaceutical company: Janssen PharmaceuticalsNEW INDICATION & DOSAGEAdjunct to diet and exercise to improve glycemic control in patients with type 2 diabetesChildren ages 10 and older: 100 mg PO once daily before the first meal of the day. May increase to 300 mg/day in patients with an estimated GFR of 60 mL/minute/1.73 m2 or greater.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.canagliflozin and metFORMIN hydrochlorideInvokamet, Invokamet XRPharmaceutical company: Johnson & JohnsonNEW INDICATION & DOSAGEAdjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes when treatment with both canagliflozin and metformin is appropriateChildren ages 10 and older currently not treated with either canagliflozin or metformin: One tablet of immediate-release canagliflozin 50 mg and metformin 500 mg PO b.i.d. with meals. Or two tablets of extended-release canagliflozin 50 mg and metformin 500 mg PO daily with morning meal.Children ages 10 and older already on metformin: Immediate-release, 50 mg canagliflozin plus previously prescribed or nearest appropriate dose of metformin in divided doses PO b.i.d. with meals. Or extended-release, 100 mg canagliflozin plus previously prescribed or nearest appropriate dose of metformin once daily with morning meal. Patients taking an evening dose of metformin extended-release should skip their last dose before starting this drug the following morning.Children ages 10 and older already on canagliflozin: Immediate-release, 500 mg metformin plus previously prescribed dose of canagliflozin in divided doses PO b.i.d. with meals. Or extended-release, 1,000 mg metformin plus previously prescribed dose of canagliflozin PO once daily with morning meal.Children ages 10 and older already on canagliflozin and metformin: Switch to the same total daily doses of each component divided PO b.i.d. with meals for immediate-release, or PO once daily with morning meal for extended-release. Patients taking an evening dose of metformin extended-release should skip their last dose before starting this drug the following morning.Adjust-a-dose: In patients who have an estimated GFR of 60 mL/minute/1.73 m2 or greater and require additional glycemic control: If tolerating immediate-release canagliflozin 50 mg b.i.d., increase the canagliflozin dose to 150 mg b.i.d., with gradual metformin dose escalation based on tolerability; if tolerating extended-release canagliflozin 100 mg once daily, increase the canagliflozin dose to 300 mg once daily, with gradual metformin dose escalation based on tolerability.Adjust-a-dose: Increase the dose gradually, if needed, to reduce metformin's GI adverse effects. Don't exceed the maximum daily dose of 2,000 mg of metformin and 300 mg of canagliflozin. Limit the total daily dose of the canagliflozin component to 100 mg in patients with abnormal kidney function with estimated GFR of 45 to less than 60 mL/minute/1.73 m2. If estimated GFR is 30 to 45 mL/minute/1.73m2, assess the benefit and risk of continuing the combination product, and limit the dose of canagliflozin component to 100 mg daily. Use is contraindicated in patients with an estimated GFR less than 30 mL/minute/1.73 m2 and in those with kidney failure with replacement therapy or who are on hemodialysis. If concomitant use of uridine 5'-diphospho-glucuronosyltransferase enzyme inducer is required, increase the total daily dose of canagliflozin to 200 mg in patients currently tolerating 100 mg daily; may increase to 300 mg daily in patients currently tolerating 200 mg daily with an estimated GFR of more than 60 mL/minute/1.73m2.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.fondaparinux sodiumArixtraPharmaceutical company: MylanNEW INDICATION & DOSAGEVenous thromboembolismChildren ages 1 and older weighing at least 10 kg to 20 kg: 0.1 mg/kg subcut daily. Round patient-specific dose to nearest 0.1 mg.Children ages 1 and older weighing more than 20 kg to 40 kg: 2.5 mg/0.5 mL prefilled syringe.Children ages 1 and older weighing more than 40 kg to 60 kg: 5 mg/0.4 mL prefilled syringe.Children ages 1 and older weighing more than 60 kg: 7.5 mg/0.6 mL prefilled syringe.Adjust-a-dose: If full prefilled syringe dosing in children weighing more than 20 kg doesn't achieve therapeutic levels, a patient-specific dose may be prepared to achieve the peak anti-Xa level target of 0.5 mg/L to 1 mg/L. If the anti-Xa level is less than 0.3 mg/L, increase the dose by 0.03 mg/kg; if the level is 0.3 mL to 0.49 g/L, increase the dose by 0.01 mg/kg. If the anti-Xa level is 1.01 mg/L to 1.2 mg/L, decrease the dose by 0.01 mg/kg; if the level is greater than 1.2 mg/L, decrease the dose by 0.03 mg/kg. Round the patient-specific dose to the nearest 0.1 mg. Maximum daily dose is 7.5 mg.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.tapinarofVtamaPharmaceutical company: Dermavant Sciences, Inc.NEW INDICATION & DOSAGEAtopic dermatitisAdults and children ages 2 and older: Apply a thin layer to affected areas once daily.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.tirzepatideZepboundPharmaceutical company: Eli Lilly and CompanyNEW INDICATION & DOSAGEModerate to severe obstructive sleep apnea in patients with obesity (Zepbound only)Adults: Initially, 2.5 mg subcut weekly for 4 weeks, then increase to 5 mg. May increase in 2.5-mg increments after at least 4 weeks at current dose. Recommended maintenance dose is 10 mg or 15 mg once weekly based on response and tolerability.Released: March 2025Nursing Drug Handbook© 2025 Wolters Kluwer N.V., its subsidiaries and/or its licensors. All rights reserved.
New Drug Indications - February 2025
New Drug Indications - January 2025
New Drug Indications - December 2024
dalteparin sodiumFragminPharmaceutical company: PfizerNEW INDICATION & DOSAGESymptomatic venous thromboembolism in childrenChildren from birth (gestational age at least 35 weeks) to younger than 2 years: 150 international units/kg subcut b.i.d. for three doses; then assess anti-Xa level.Adjust-a-dose: Adjust dosage in increments of 25 international units/kg to achieve target anti-Xa level between 0.5 and 1 international unit/mL. If the platelet count is 50,000 to 100,000/mm3, reduce dosage by 50% until platelet count exceeds 100,000/mm3. If the platelet count is less than 50,000/mm3, stop the drug until the platelet count exceeds 50,000/mm3.Released: December 2024Nursing Drug Handbook© 2024 Wolters KluwerdupilumabDupixentPharmaceutical company: Sanofi and Regeneron PharmaceuticalsNEW INDICATION & DOSAGEAdd-on maintenance treatment for inadequately controlled COPD and an eosinophilic phenotypeAdults: 300 mg subcut every other week.Released: December 2024Nursing Drug Handbook© 2024 Wolters KluwernivolumabOpdivoPharmaceutical company: Bristol Myers SquibbNEW INDICATION & DOSAGENeoadjuvant treatment of resectable non–small-cell lung cancer (tumors at least 4 cm or node-positive) without known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, in combination with platinum-doublet chemotherapy; followed by single-agent nivolumab as adjuvant treatmentAdults: 360-mg IV infusion with platinum-doublet chemotherapy on the same day every 3 weeks for up to 4 cycles or until disease progression or unacceptable toxicity occurs; then as a single-agent, 480 mg every 4 weeks after surgery for up to 13 cycles or until disease recurrence or unacceptable toxicity occurs.  Released: December 2024Nursing Drug Handbook© 2024 Wolters KluweronabotulinumtoxinABotox CosmeticPharmaceutical company: Allergan Aesthetics/AbbVieINDICATION & DOSAGETemporary improvement in the appearance of moderate to severe platysma bands associated with platysma muscle activityAdults: 2 units (0.05 mL) IM into each of four sites in the upper segment of the platysma muscles below the jawline on each side; and 1 unit (0.025 mL) into five sites on each vertical neck band per side (1 to 2 bands per side). Depending on platysma band severity, total dose may be 26 units (1 band per side), 31 units (1 band one side, 2 bands other side), or 36 units (2 bands each side). Administer no more frequently than every 3 months.Released: December 2024Nursing Drug Handbook© 2024 Wolters KluwerosimertinibTagrissoPharmaceutical company: AstraZenecaNEW INDICATION & DOSAGELocally advanced, unresectable (stage III) non–small-cell lung cancer in patients whose disease hasn't progressed during or after concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutationsAdults: 80 mg PO once daily until disease progression or unacceptable toxicity occurs.Released: December 2024Nursing Drug Handbook© 2024 Wolters Kluwer
New Drug Indications - November 2024
certolizumab pegolCimziaPharmaceutical company: UCB, Inc.NEW INDICATION & DOSAGEActive polyarticular juvenile idiopathic arthritisAdults and children ages 2 and older weighing 40 kg or more: 400 mg subcut at weeks 0, 2, and 4; then maintenance dose of 200 mg every 2 weeks.Adults and children ages 2 and older weighing 20 to less than 40 kg: 200 mg subcut at weeks 0, 2, and 4; then maintenance dose of 100 mg every 2 weeks.Adults and children ages 2 and older weighing 10 to less than 20 kg: 100 mg subcut at weeks 0, 2, and 4; then maintenance dose of 50 mg every 2 weeks.Released: November 2024Nursing Drug Handbook© 2024 Wolters KluwerletermovirPrevymisPharmaceutical company: Merck & Co.NEW AVAILABLE FORMOral pellets: 20 mg; 120 mg packetNEW INDICATION & DOSAGEProphylaxis of cytomegalovirus (CMV) infection and disease in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT)Children age 12 and older weighing at least 30 kg: 480 mg PO or IV infusion once daily through 100 days post-HSCT.Children ages 6 months to younger than 12 years weighing 15 to less than 30 kg: 240 mg PO or 120-mg IV infusion once daily through 100 days post-HSCT.Children ages 6 months to younger than 12 years weighing 7.5 to less than 15 kg: 120-mg oral pellets or 60-mg IV infusion once daily through 100 days post-HSCT.Children ages 6 months to younger than 12 years weighing 6 to less than 7.5 kg: 80-mg oral pellets or 40-mg IV infusion once daily through 100 days post-HSCT.Adjust-a-dose: May begin therapy between day 0 and day 28 post-HSCT. In patients at risk for late CMV infection and disease, may continue through 200 days post-HSCT. If coadministered with cyclosporine, decrease the dose to 240 mg PO or IV once daily in children age 12 and older weighing at least 30 kg; 120 mg in children younger than age 12 weighing 15 to less than 30 kg; 60 mg in children younger than age 12 weighing 7.5 to less than 15 kg; or 40 mg in children younger than age 12 weighing 6 to less than 7.5 kg. If initiating cyclosporine after start of letermovir, decrease the next dose of letermovir. If cyclosporine is discontinued after starting letermovir, increase the next dose of letermovir. If cyclosporine dosing is interrupted because of high cyclosporine level, no letermovir dose adjustment is needed.Prophylaxis of CMV disease in patients who are kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative)Adults and children ages 12 and older weighing at least 40 kg: 480 mg PO or IV infusion once daily through 200 days posttransplant.Adjust-a-dose: May begin therapy between day 0 and day 7 posttransplant. If coadministered with cyclosporine, decrease the dose to 240 mg PO or IV once daily. If cyclosporine is initiated after start of letermovir, decrease the next dose of letermovir to 240 mg once daily. If cyclosporine is discontinued after starting letermovir, increase the next dose of letermovir to 480 mg once daily. If cyclosporine dosing is interrupted because of high cyclosporine level, no letermovir dose adjustment is needed.Released: November 2024Nursing Drug Handbook© 2024 Wolters KluwerpembrolizumabKeytrudaPharmaceutical company: Merck & Co.NEW INDICATION & DOSAGEFirst-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma, in combination with pemetrexed and platinum chemotherapyAdults: 200-mg IV infusion every 3 weeks or 400-mg IV infusion every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in patients without disease progression. Give before chemotherapy when given the same day.  Released: November 2024Nursing Drug Handbook© 2024 Wolters KluwerribociclibKisqaliPharmaceutical company: NovartisINDICATION & DOSAGEAdjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, stage II and III early breast cancer in patients at high risk for recurrence, in combination with an aromatase inhibitorAdults: 400 mg PO once daily for 21 consecutive days followed by 7 days off therapy. Continue for 3 years, or until disease recurrence or unacceptable toxicity occurs. Refer to the aromatase inhibitor prescribing information for dosage and administration specifics.Adjust-a-dose: For patients with early breast cancer and Child-Pugh class B or C liver impairment, no dose adjustment is necessary. If use with a strong CYP3A inhibitor can't be avoided, reduce ribociclib dose to 200 mg once daily; allow 5 half-lives of the inhibitor after discontinuation of the inhibitor before returning to the initial ribociclib dose.Released: November 2024Nursing Drug Handbook© 2024 Wolters Kluwer
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >| 
Displaying results 1-9 (of 51)

CE Resources

Nursing Resources

About NursingCenter

 

© 2025 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer – Your California Privacy Choices -- v10.05.00